Hepatic Impairment Soon after oral administration of just one 4 mg dose (2 mg hydromorphone quick-release tablets), necessarily mean exposure to hydromorphone (Cmax and AUC?) is increased 4-fold in clients with average (Kid-Pugh Group B) hepatic impairment compared with topics with typical hepatic purpose. Due to elevated publicity of hydromorphone